Saturday, 31 October 2026European Markets

ALLFUNDS GROUP Stock Bearish Momentum With A 31% Fall In The Last 21 Sessions

Loading stream...

(VIANEWS) - Shares of ALLFUNDS GROUP (AEX-Index: ALLFG.AS) fell by a staggering 31.86% in 21 sessions from €8.57 to €5.84 at 14:09 EST on Monday, after five consecutive sessions in a row of losses. AEX-Index is jumping 1.01% to €739.21, following the last session's downward trend.

ALLFUNDS GROUP's last close was €5.80, 46.25% under its 52-week high of €10.79.

About ALLFUNDS GROUP

Allfunds Group plc provides B2B WealthTech platforms connecting fund houses and distributors in the United Kingdom and internationally. It operates an open-architecture platform that provides a marketplace and digital solutions matching fragmented demand for asset management products from distributors with fragmented supply of products from fund houses. Its ecosystem covers fund distribution value chain and investment cycle, including via Allfunds Connect, a suite of SaaS-enabled digital, data, and analytics tools. The company also provides asset holding, banking and investment, representation, computer programming and technology development, and institutional intermediation services, as well as research and regulatory services. Allfunds Group plc was founded in 2000 and is based in London, the United Kingdom.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 3.09%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 13.1%, now sitting on 2.83B for the twelve trailing months.

More news about ALLFUNDS GROUP (ALLFG.AS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com